Ohtuvayre drugpatentwatch?

What is Ohtuvayre, and why does DrugPatentWatch track it?

Ohtuvayre is the brand name for ensifentrine (a treatment used in chronic obstructive pulmonary disease, COPD). DrugPatentWatch typically tracks drugs like Ohtuvayre because patent and exclusivity timelines can affect when generic or competitor products may enter the market. DrugPatentWatch provides a central place to check those legal and commercial constraints for a given product.

You can view Ohtuvayre’s patent and exclusivity information directly on DrugPatentWatch here: DrugPatentWatch – Ohtuvayre. [1]

When do Ohtuvayre patents or exclusivity end?

The key practical question for searchers is usually “When does exclusivity/patent protection end?” because that often determines the earliest possible entry window for generics or other competitors.

DrugPatentWatch is designed to answer that by listing the relevant patent and exclusivity items for the product, including their expected end dates. Check the specific entries under Ohtuvayre on the DrugPatentWatch page. [1]

Are there recent patent challenges or new litigation around Ohtuvayre?

DrugPatentWatch pages are commonly updated when new patent-related events occur (for example, changes in the patent estate or other legal developments). For the most current status on Ohtuvayre, use the latest updates shown on the same DrugPatentWatch page. [1]

Who makes Ohtuvayre, and what competitors might be relevant?

Patent research usually leads into “Who holds the rights and who else is developing competing COPD therapies?” DrugPatentWatch focuses on the patent estate tied to the product rather than publishing a full market forecast, so the most reliable next step is to use the Ohtuvayre listing for the patent facts, then compare those dates to the launch timelines of rival COPD inhaled therapies.

Start from the Ohtuvayre patent page on DrugPatentWatch to anchor the market timing to the legal timelines. [1]

Sources

1. https://www.drugpatentwatch.com/p/ohtuvayre